Pfizer recalls Dopamine HCl Inj.
- Recalling company
- Pfizer
- Product
- Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
- Reason
- Lack of Assurance of Sterility
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Sep 4, 2026
- Reported
- Sep 23, 2026
- Distribution
- US Nationwide.
- Status
- Ongoing
- Quantity
- N/A
- Lot / codes
- Lot # NL5230, Exp Date:10/2027
- Company location
- Manhattan, NY
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0853-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0853-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.